We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

ML Model Combines Imaging, Clinical, and DNA Methylation Biomarkers for Early Lung Cancer Detection

By LabMedica International staff writers
Posted on 17 Aug 2023
Print article
Image: A combined ML model enables accurate classification of pulmonary nodules (Photo courtesy of Freepik)
Image: A combined ML model enables accurate classification of pulmonary nodules (Photo courtesy of Freepik)

Lung cancer is responsible for a significant number of cancer-related deaths around the globe. Although various treatments, including chemotherapy, immunotherapy, and surgery, have progressed, the overall outlook for lung cancer patients remains grim. This mainly stems from late diagnosis, often at stages III or IV, when the five-year survival rate falls below 10%. Early detection at stages 0–II could significantly lower mortality, but the lack of sensitive technologies and noticeable symptoms in early stages presents substantial challenges.

Deoxyribonucleic acid (DNA) methylation biomarkers have shown potential for early lung cancer detection, as they indicate events connected to tumor initiation. The use of next-generation sequencing methods to identify methylation patterns in circulating tumor DNA could enable non-invasive lung cancer screening. While low-dose computerized tomography (LDCT) has been effective in early detection among high-risk groups, determining the malignancy risk of pulmonary nodules via LDCT remains a challenge. Now, researchers have developed and validated a combined machine learning model comprising imaging, clinical, and cell-free DNA methylation biomarkers that improves the classification of pulmonary nodules and enables earlier diagnosis of lung cancer.

In the new study, researchers at Guangzhou Medical University (Guangzhou, China) developed a combined model of clinical and imaging biomarkers (CIBM) that uses machine learning algorithms to differentiate malignant and benign pulmonary nodules. When integrated with PulmoSeek, a pre-existing cell-free DNA methylation model, the CIBM model can identify small-sized nodules to diagnose lung cancer in its initial stages. For their study, the researchers conducted a study involving participants 18 years and older, with specific types of pulmonary nodules, across 20 Chinese cities. Utilizing over 800 samples, the researchers trained the machine-learning algorithm of the CIBM model to distinguish between benign and malignant tumors. This CIBM model was then integrated with PulmoSeek to create PulmoSeek Plus, a combined diagnostic model. Using decision curve analysis, the team evaluated its clinical application, classifying nodules into risk groups. The aim was to evaluate the performance and diagnostic ability of three models: PulmoSeek, CIBM, and PulmoSeek Plus.

The results showed that PulmoSeek Plus holds the potential for successful early-stage diagnosis of benign or malignant pulmonary nodules. Used in conjunction with LDCT, this model could be a powerful tool in the early clinical evaluation of lung cancer. The combination of CIBM with the PulmoSeek model heightened the sensitivity of nodule classification by 6% and the negative predictive value by 24%. Moreover, the model’s performance remained strong across different types, sizes, and stages of pulmonary nodules, with sensitivities of characterization for early-stage and small nodules at 0.98 and 0.99, respectively. Particularly noteworthy was its 100% characterization sensitivity for sub-solid nodules, which are typically hard to categorize using LDCT alone. The creation of the PulmoSeek Plus model marks a significant advancement in early lung cancer detection. Given its sole requirement of non-invasive blood samples and CT images, the model offers an efficient and promising approach that could fundamentally change how lung cancer is diagnosed and managed.

Related Links:
Guangzhou Medical University 

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Complement 3 (C3) Test
GPP-100 C3 Kit
Chikungunya & Dengue Virus Test

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: The PrismRA blood test helps target best treatments for patients with rheumatoid arthritis (Photo courtesy of Scipher Medicine)

Groundbreaking Rheumatoid Arthritis Blood Test Predicts Treatment Response

Rheumatoid arthritis (RA), an autoimmune disease affecting joints and other systems in the body, impacts millions globally. Typically, the initial biologic treatment involves anti-inflammatory drugs from... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.